BioSpace News Archive

CorMedix Inc. announced that it has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath®.

GRI Bio, Inc. today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.

Entera Bio Ltd. announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).

NRx Pharmaceuticals, Inc. today announced that the Company has achieved data-lock in its Phase 2b /3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.

Lucid Diagnostics Inc. today announced that Lucid’s President & Chief Operating Officer Shaun O’Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology’s World Congress of Nephrology.

Jaguar Health, Inc. today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the publication of a new study, highlighting the effectiveness of Lunit INSIGHT MMG in significantly reducing radiologists’ workload while enhancing cancer detection rates.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS ® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS).

Kytopen Corp. today announced the appointment of Kevin Gutshall as Chief Commercial Officer, effective April 1st, 2024.